Navigation Links
European Regulatory Agency Accepts Cell Therapeutics, Inc.'s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Date:4/1/2008

process for XYOTAX," said James A. Bianco, M.D., President and CEO of CTI. "This is an important step toward making XYOTAX available for lung cancer patients in Europe."

About Lung Cancer

Lung cancer is the most common malignancy worldwide. Non-small cell lung cancer (NSCLC) accounts for 80 percent of all lung cancer cases. Within the population of patients with NSCLC requiring chemotherapy, PS2 patients, which account for approximately 25 percent of this group, are a population with special requirements since they have poor survival with cytotoxic chemotherapy and targeted agents. PS2 patients represent a subgroup of patients who are ambulatory and capable of self-care, but are unable to carry out any work activities, although they are up and about more than 50 percent of waking hours. There are presently no drugs approved to treat PS2 patients with advanced NSCLC.

Lung cancer remains the biggest cancer killer in Europe. The incidence of lung cancer in Europe is more than 13 percent of all cancers, and in 2000 resulted in nearly 350,000 deaths.

About XYOTAX(TM)

XYOTAX(TM) (paclitaxel poliglumex, CT-2103) is an investigational, biologically enhanced, chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable polyglutamate polymer, which results in a new chemical entity. When bound to the polymer, the chemotherapy is rendered inactive, potentially sparing normal tissue's exposure to high levels of unbound, active chemotherapy and its associated toxicities. Blood vessels in tumor tissue, unlike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that XYOTAX is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer,
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. European Experts Recommend Pregnant and Nursing Women Take More DHA - Every Day
4. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
5. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
6. Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO)
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
9. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
10. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
11. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 2015 Asterias Biotherapeutics, Inc. (NYSE MKT: ... field of regenerative medicine, today announced that the ... community to review the clinical development strategy for ... on Friday, May 8, 2015. Topics will include ... planned clinical activities for AST-OPC1. ...
(Date:5/6/2015)... INCLINE VILLAGE, Nev., May 6, 2015 PDL BioPharma, ... results for the first quarter ended March 31, 2015. ... 2015 increased nine percent to $149.7 million from $136.8 ... the quarter ended March 31, 2015 included $127.8 million ... the Queen et al. patents, $11.4 million in net ...
(Date:5/6/2015)... 6, 2015 Lannett Company, Inc. (NYSE: ... 2015 third quarter ended March 31, 2015.  ... rose 24% to $99.4 million from $80.0 million in ... $75.6 million, or 76% of net sales, from $56.1 ... (R&D) expenses decreased to $9.2 million from $10.6 million ...
Breaking Medicine Technology:Asterias Biotherapeutics to Host Investor Meeting to Review Clinical Development Strategy for AST-OPC1 in Spinal Cord Injury 2Asterias Biotherapeutics to Host Investor Meeting to Review Clinical Development Strategy for AST-OPC1 in Spinal Cord Injury 3PDL BioPharma Announces First Quarter 2015 Financial Results 2PDL BioPharma Announces First Quarter 2015 Financial Results 3PDL BioPharma Announces First Quarter 2015 Financial Results 4PDL BioPharma Announces First Quarter 2015 Financial Results 5PDL BioPharma Announces First Quarter 2015 Financial Results 6PDL BioPharma Announces First Quarter 2015 Financial Results 7Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 2Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 3Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 4Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 5Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 6Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 7Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 8
... Schein, Inc. (Nasdaq: HSIC ), the largest provider ... today that it will release its third quarter 2010 financial ... 2010, and will provide a live webcast of its earnings ... Eastern Daylight Time. Speakers on the call will include Stanley ...
... PITTSBURGH, Oct. 15 Mylan Inc. (Nasdaq: ... Inc. received final approvals from the U.S. Food and ... (ANDAs) for the generic versions of Hyzaar® Tablets, 50 ... 25 mg, 50 mg and 100 mg, both antihypertensives. ...
Cached Medicine Technology:Henry Schein to Webcast Third Quarter 2010 Conference Call Friday, October 29, at 10:00 a.m. EDT 2Mylan Receives Approvals for Generic Versions of Hyzaar® and Cozaar® 2
(Date:5/6/2015)... May 06, 2015 Corporate Executives ... of MEBC, an Alliance Award for excellence in ... FOCUS 2015, JDA’s annual user conference which brought ... and wholesale distribution sectors. This award recognizes MEBC, ... receiving services that advance their supply chain performance ...
(Date:5/6/2015)... May 06, 2015 The Beryl Institute ... of Patient Experience Journal (PXJ), an international, open ... around understanding and improving patient experience. The second volume ... experience conversation globally, helps align the voices engaged and ... , Published in association with The Beryl Institute, Volume ...
(Date:5/6/2015)... Los Angeles (PRWEB) May 06, 2015 ... WaterAid, the #1 ranked international water, sanitation and hygiene ... work for communities across the world and it brings ... Lindsey Carnett, CEO of Marketing Maven. “The ongoing relationship ... the opportunities available for people to learn about and ...
(Date:5/6/2015)... Waltham, MA (PRWEB) May 06, 2015 ... information for healthcare professionals and students, announced today that ... UpToDate®, 94% confirmed that use of the clinical decision ... Additionally, by the end of 2014, UpToDate users in ... million clinical topics per month, on average. In Germany ...
(Date:5/6/2015)... TU-Automotive has opened press registration for TU-Automotive ... it to the headlines of major publications world-wide. With ... and Hyundai ready to share their visions for the ... way for press to go behind the scenes and ... TU-Automotive said “This year we’re releasing a preview of ...
Breaking Medicine News(10 mins):Health News:MEBC Receives Award for Consulting Excellence in Retail 2Health News:Patient Experience Journal Releases Spring 2015 Issue 2Health News:Marketing Maven Expands Partnership with the #1 Ranked International Water, Sanitation and Hygiene Nonprofit 2Health News:Marketing Maven Expands Partnership with the #1 Ranked International Water, Sanitation and Hygiene Nonprofit 3Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 2Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 3Health News:Press Registration for TU-Automotive Detroit Now Open 2
... LUGANO, Switzerland, September 9 As part of the ... as new,CEO in the American subsidiary, Helsinn Therapeutics (U.S.) ... the recently acquired,Helsinn Therapeutics, and has held leadership positions ... in Research. , Moreover, Helsinn ...
... ... with medically inoperable lung cancer. , ... Phoenix, Arizona (Vocus) September 9, 2009 -- Today, DoctorFinders.com ( http://doctorfinders.com/ ... medically inoperable lung cancer ., , , , ,Medically inoperable cancer can be ...
... ... Cosmetic Dentistry, well known for dental care as well as cosmetic and sedation dentistry, ... ... 9, 2009 -- Raleigh Comprehensive and Cosmetic Dentistry, led by Dr. Robert L. Williamson ...
... , - Choosing a More Appropriate ... to Improvement , The first results of ... presented today at the 6th congress,of the European Federation of Chapters ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090909/358726 ) , ...
... light, 300 million metres per second, was long thought ... matter and energy but recent research in the area ... manipulate light to some ingenious and hugely lucrative ends. ... perfect images of distant galaxies or detailed representations inside ...
... infectious bacteria in an experimental system, researchers at University ... in the body the bacteria go giving an ... to the development of more targeted treatments. At ... Edinburgh, Dr Cormac Gahan described how his research team ...
Cached Medicine News:Health News:New Chief Executive Officer and Vice President Commercial Operations USA at the Helsinn Group's American subsidiary, Helsinn Therapeutics (U.S.) Inc. 2Health News:CyberKnife Treatment for Medically Inoperable Lung Cancer 2Health News:Raleigh Comprehensive and Cosmetic Dentistry Announces Addition of New Practice to Raleigh Dentist Family 2Health News:First Results From Major European Patient Survey Show Devastating Impact of Living With Breakthrough Cancer Pain 2Health News:First Results From Major European Patient Survey Show Devastating Impact of Living With Breakthrough Cancer Pain 3Health News:Light at the speed of a bicycle and much more 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: